BUZZ-China's AIM jumps on approval of vaccine's clinical trial in US

Shares of AIM Vaccine Co Ltd 6660.HK jump as much as 13.2% to HK$6.35; on course for biggest one-day gain since October 17, 2024

Stock on track for the second session of gain

AIM says U.S. Food and Drug Administration (FDA) has approved its application for clinical trial of mRNA respiratory syncytial virus vaccines

The Chinese mRNA vaccine products developer says it is U.S. FDA's first approval for the company's products, marking a "significant progress" for its global strategy

Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI both add 0.1%, healthcare index .HSCIH gains 0.2%

Stock up 1.5% YTD